SR One related stories
All articles and analysis
- RaNA Therapeutics Inks $20.7M
Cambridge, Mass.-based RaNA Therapeutics Inc. has raised $20.7 million in a round of financing co-led by Atlas Venture, SR One and Monsanto, with participation of Partners Innovation Fund. The money will be used for continued development of RaNA’s technology platform to “enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA,” the company says.
- SpringLeaf Therapeutics Closes on $4M
SpringLeaf Therapeutics held a second closing of its Series B round, inking an additional $4 million from new investor Excel Venture Management. The total for the round now stands at $19 million. The company’s other investors include SR One, Flybridge Capital Partners, and North Bridge Venture Partners. SpringLeaf is based in Boston.
- Nimbus Discovery Inks $24M Series A
Biopharma company Nimbus Discovery has closed on a $24 million Series A round co-led by Atlas Venture, SR One, and Lilly Ventures. Existing investor, Bill Gates, also participated, the company said. Nimbus uses computational technology to discover medicines for difficult-to-drug diseases, and will use the infusion of capital to accelerate its existing development programs. The company closed on an undisclosed amount of seed financing in March.
- HTG Molecular Diagnostics Raises $16.2M
HTG Molecular Diagnostics, a Tuscon-based provider of molecular technology, has raised $16.2 million in Series D financing. Investors include SR One, the corporate venture capital arm of GlaxoSmithKline, as well as Novo A/S, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures. Novo A/S led the round. Simeon George, partner at SR One will now join the company’s board.